Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study

Head and Neck Neoplasms Clinical Trial

— SupCare  

Official title:

Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06347185
• Other study ID #: EORTC-2236-HNCG-QLG
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 2024
• Est. completion date: December 2028

Study information

• Verified date: April 2024
• Source: European Organisation for Research and Treatment of Cancer - EORTC
• Contact: EORTC HQ
• Phone: +3227741611
• Email: eortc[@]eortc.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a late phase II, prospective, multicenter randomized study, to assess the value of early palliative care integrated with the standard oncologic care in patients with Recurrent Metastatic (RM) Head and Neck Cancer (HNC) proposed to first line palliative systemic treatment.

The study randomizes patients in a 1:1 fashion to standard oncologic care, in which the palliative care is requested as needed (reactive approach) or to early palliative care integrated with the standard oncologic care (proactive approach).

Standard of Care: the oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise. The oncologist will base the choices also upon the results of the Liverpool Head and Neck Patient Concern Inventory (PCI-H&N) and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.

Integrated approach: Besides the Oncology visit, patient will have the palliative care expert visit and follow up. The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to a validated instrument (the PCI-H&N) and patient priority questionnaire's results.

Stratification Factors

• Institution

• Performance Status (PS) (0 vs 1-2)

• Presence of any caregiver at home

• Type of treatment (Immunotherapy alone vs any other combination)

Study duration: the total study duration is estimated at 36 months, with a total accrual time estimated to be 24 months from first patient in (FPI) and with an additional follow-up period of 12 months.

End of study occurs when all patients have completed their end of study visit and the study is mature for all analyses defined in the protocol and the database has been cleaned and frozen for these analyses.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 160
• Est. completion date: December 2028
• Est. primary completion date: April 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients over 18 years of age

• Histological diagnosis of HNC of epithelial origin. Any sub-site of head and neck is eligible except endocrine tumours such as thyroid and parathyroid cancer

• First diagnosis of recurrent disease and/or distant metastasis; with recurrent disease not amenable to salvage surgery or re-irradiation

• Patient candidate to any first line systemic treatment

• Life expectancy more than 3 months

• PS Eastern Cooperative Oncology Group (ECOG) =2

• Adequate cognitive and reading abilities.

• Availability of baseline scores for Emotional Functioning and Pain

• Patient agrees to complete questionnaires at week 6, 15, 24 and 52 after systemic treatment start

• Before patient 's enrolment, written informed consent must be given according to International Council for Harmonisation (ICH)/Good Clinical Practice (GCP), and national/local regulations.

Exclusion Criteria:

• Patients requiring a palliative care consultation right from the beginning of treatment

• Cutaneous primary cancer

• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the study

Related Conditions & MeSH terms

• Head and Neck Neoplasms

Intervention

Procedure:
• Early palliative care, integrated with the standard oncologic care (proactive approach)
Besides the Oncology visit, patient will have the palliative care expert visit and follow up (proactive approach). The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to the Liverpool Head and Neck Patient Concern Inventory (PCI-H&N) and patient priority questionnaire's results.
• Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)
The oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise (reactive approach). The oncologist will base the choices also upon the results of the PCI-H&N and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
European Organisation for Research and Treatment of Cancer - EORTC

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in emotional functioning and pain scores according to Item List (IL) 250 questionnaire at 15 weeks.	To assess the added value of early palliative care integrated with the standard oncologic care as measured by the difference in mean change from baseline to 15 weeks between arms in patient reported emotional functioning and pain.; Minimum = -100; Maximum = +100; higher means better outcome	at 15 weeks
Secondary	Change from baseline in emotional functioning and pain scores according to Item List 250 (IL250) questionnaire at 6 weeks, 24 weeks and 52 weeks.	Evaluate the added value of early palliative care integrated with the standard oncologic care as measured by the difference in mean change from baseline at alternative timepoints between arms in patient reported emotional functioning and pain.; Minimum = -100; Maximum = +100; higher means better outcome	at 6 weeks, 24 weeks and 52 weeks
Secondary	Change from baseline in the selected Health Related Quality of Life (HRQoL) scales from the Item List 250 (IL250) questionnaire at 6 weeks, 15 weeks, 24 weeks and 52 weeks	Evaluate the change from baseline in supportive patient-reported symptom and functional outcomes at 6 weeks, 15 weeks, 24 weeks and 52 weeks.; Minimum = -100; Maximum = +100; higher means better outcome	at 6 weeks, 15 weeks, 24 weeks and 52 weeks
Secondary	Number of unplanned visits to emergency room or specialist visits	Evaluate the frequency of the unplanned access to emergency room or specialist visits	up to 52 weeks
Secondary	Hospitalization due to treatment toxicities or tumour signs/symptoms, as evaluated by number of admissions and duration	Frequency of hospitalization due to adverse effects of treatment or due to tumour symptoms/signs	up to 52 weeks
Secondary	Identification of the rate of patients starting a new systemic treatment in the last three months of life	Frequency of oncological treatments in last three months of life.	until 1 year from last patient enrolled
Secondary	Rate of patients receiving systemic treatment in the last month of life	Identification of the rate of patients receiving systemic treatment in the last month of life	until 1 year from last patient enrolled
Secondary	Rate of patients with a tracheostomy performed in the last 3 months of life	Identification of the rate of patients with tracheostomy performed in the last 3 months of life.	until 1 year from last patient enrolled
Secondary	Rate of patients with gastrostomy performed in the last 3 months of life	Identification of the rate of patients with gastrostomy performed in the last 3 months of life.	until 1 year from last patient enrolled
Secondary	Caregiver/family members' satisfaction (FAMcare questionnaire) at 15 weeks	Assessment of the caregiver/family members' satisfaction. Minimum = -99; Maximum = +99; higher means better outcome.	at 15 weeks
Secondary	Overall Survival (OS)	Overall Survival	until 1 year from last patient enrolled
Secondary	Prediction error of survival (defined as the difference between actual survival (AS) of patients and clinician prediction of survival (CPS))	Accuracy of physician prediction of survival	until 1 year from last patient enrolled